ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Microbiome firms raise big money

by Lisa M. Jarvis
April 25, 2016 | APPEARED IN VOLUME 94, ISSUE 17

The venture arms of Pfizer and Roche have led a $43 million round of financing for Second Genome, which is developing small molecules that modulate the microbiome. Second Genome plans to use the cash to expand drug discovery and support clinical trials for SGM-1019, which is in development to treat ulcerative colitis. Separately, Enterome Bioscience has raised $16 million in its third round of financing, in which Nestlé Health Science joined as a new investor. The microbiome-focused firm will use the proceeds to put EB8018, a small-molecule FimH antagonist recently licensed from Vertex Pharmaceuticals, into clinical studies for inflammatory bowel disease.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment